R. Kate Kelley, MD
Clinical trials continue to investigate the use of immunotherapy agents in advanced hepatocellular carcinoma (HCC), especially with the phase III CheckMate-459 trial in which nivolumab (Opdivo) is being compared with sorafenib (Nexavar) in the frontline setting.
on Gastrointestinal Cancers, Kelley, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discussed the incidence of and risk factors for HCC, and emphasized the sequence of clinical trials that characterized the field in 2017.
OncLive®: What is the current state of HCC?
: HCC is dramatically on the rise; it’s the number 1 rising cause of cancer death in the United States. HCC is projected to increase even further because of rising risk factors like fatty liver disease, which is an epidemic in the Western world. Historically, we have only really had 1 systemic therapy for advanced disease, which is the multikinase inhibitor sorafenib. Sorafenib was approved in 2007 based upon the randomized phase III SHARP trial.
... to read the full story